Other autoimmune hemolytic anemia
ICD-10 D59.19 is a billable code used to indicate a diagnosis of other autoimmune hemolytic anemia.
Other autoimmune hemolytic anemia (AIHA) refers to a group of disorders characterized by the immune system mistakenly attacking and destroying red blood cells, leading to hemolytic anemia. This condition can be classified into warm and cold AIHA, depending on the temperature at which the antibodies react with red blood cells. Patients may present with symptoms such as fatigue, pallor, jaundice, and splenomegaly. The etiology of AIHA can be idiopathic or secondary to other conditions, including infections, malignancies, or autoimmune diseases. Diagnosis typically involves laboratory tests such as a complete blood count (CBC), reticulocyte count, direct Coombs test, and peripheral blood smear. Treatment options may include corticosteroids, immunosuppressive agents, or splenectomy, depending on the severity and underlying cause. Understanding the nuances of AIHA is crucial for accurate coding and management, as it can overlap with other hemolytic anemias, enzyme deficiencies, and genetic disorders like thalassemias and sickle cell disease.
Detailed lab results, patient history, and treatment plans.
Diagnosis and management of AIHA, monitoring treatment response.
Ensure clarity in distinguishing AIHA from other hemolytic anemias.
Comprehensive autoimmune disease history and related lab tests.
AIHA as a secondary condition to autoimmune disorders.
Document any associated autoimmune conditions that may influence treatment.
Used to evaluate anemia and monitor treatment response.
Document the reason for the CBC and any relevant clinical findings.
Hematologists may require additional tests to assess hemolysis.
Warm AIHA occurs when antibodies react at body temperature, leading to hemolysis, while cold AIHA occurs when antibodies react at lower temperatures, often causing hemolysis in peripheral areas of the body.
